🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Proud to share our group latest paper in Nature. "Spatial immune scoring system predicts hepatocellular carcinoma recurrence." A game-changer for early-stage HCC management - high risk patients benefited from Immunotherapy - Dawn of Spatial Medicine? nature.com/articles/s4158… Our

Spotiphy (spot imager with pseudo-single-cell-resolution histology), a computational toolkit that transforms sequencing-based spatial transcriptomics data into single-cell-resolved whole-transcriptome images. nature.com/articles/s4159…

Tx AACR for highlighting our SITC #Checkpoints performance rocking the #AACR25 annual reception in Chicago - Sunday, April 27. The best #cancer science & the best party! Hope everyone will be there! Dr. Patrick Hwu Dr. Brad Reinfeld, MD PhD Rachel Humphrey aacr.org/blog/2025/03/1…

A Society for Immunotherapy of Cancer vision statement on accelerating #clinicaltrials to get 100 immunotherapy regulatory approvals in 10 years. Excited to be part of this effort for the paper, for our field but most importantly for the people w #cancer we are working to #cure! jitc.bmj.com/content/13/3/e…

📢 New research out today on #TILTherapy for GI cancers ❓Can neoantigen-specific tumor-infiltrating lymphocytes (TILs) improve immunotherapy for gastrointestinal cancers? ➡️ In this study, published in Nature Medicine, Lowery, et al. National Cancer Institute found that expanding TILs that

Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss Nature Cancer nature.com/articles/s4301…

Extremely excited re: IMA203 - PRAME TCR T cells Ph 1 study published in Nature Medicine! This is a transformative Rx in #melanoma for HLA-A201+ & PD1 refractory pts. Compared to TIL, easier to make, less toxic & so far ~2x response rate in heavily pre-Rx. nature.com/articles/s4159…

Talking IMA203 & SUPRAME trial #iwCART25 in Miami last wknd. Pass the word to #melanoma patients needing novel therapeutics. After ICI, this Rx has possibility for long-term dz control! Trial opening USA & Europe. 1st pt got IMA203 in Pittsburgh last week! clinicaltrials.gov/study/NCT06743…

Commentary Cancer Cell Ton Schumacher Lab Learning the language of T cell receptors through large-scale screening cell.com/cancer-cell/fu…

VIP tickets are available now! The CheckPoints will be back in Chicago on June 1 at Buddy Guy’s Legends. Donations will support SITC’s Forward Fund and benefit the next generation of cancer immunotherapy experts. LEARN MORE: sitcancer.org/funding/the-ch… #RockinForACure

Excited to help lead Phase 2/3 frontline metastatic #melanoma TeLuRide-006 study of pembro +/- novel IV TLR7/8 agonist EIK1001. Super interesting pre-clinical & prelim responses in PD1 refractory dz. Trial is open in #Pittsburgh & globally for accrual! clinicaltrials.gov/study/NCT06697…

Review Annual Reviews TNF/TNFR Superfamily Members in Costimulation of T Cell Responses—Revisited annualreviews.org/content/journa…

Time for the #AACR25 Annual Reception, featuring the #Checkpoints! Be there tonight 830 PM at McCormick Place West (Level 3) in the Skyline Ballroom (W375). We have a bunch of new tunes & rehearsal was great! AACR Dr. Patrick Hwu Rachel Humphrey Dr. Brad Reinfeld, MD PhD

Had the best time performing with Society for Immunotherapy of Cancer’s band, #TheCheckpoints AACR annual reception last night! #AACR25 🤘🎹 Russell Pachynski Jason Luke, MD, FACP Rachel Humphrey Dr. Brad Reinfeld, MD PhD Society for Immunotherapy of Cancer DocsWhoRock

Important publicly available resource from Tirosh Lab Weizmann Institute in Nature Cancer The Curated Cancer Cell Atlas provides a comprehensive characterization of tumors at single-cell resolution nature.com/articles/s4301… 124 single cell datasets across 40 cancers, >2800 samples.

🔥 NEW Targets & Modalities at #ASCO25 – DevTherapeutics Spotlight 1️⃣ B7-H4 ADC (Emi-Le) 2️⃣ PD-L1/4-1BB bispecific (LBL-024) 3️⃣ PRAME TCR-T (IMA203) 4️⃣ CLDN6×CD3 mRNA bispecific 5️⃣ KRAS G12D inhibitor 6️⃣ WT1 oral cancer vaccine 7️⃣ [²¹²Pb] VMT-α-NET 8️⃣ IL-2α-bias fusion Ab 9️⃣

The CheckPoints are ready to party - join us tonight Sunday June 1 at Buddy Guys! Best party of #ASCO25 & all for the great cause of the Society for Immunotherapy of Cancer Forward Fund that supports post-doc & trainee awards. See you tonight!!!

📹Watch our #ASCO25 poster interview with Jason Luke, MD, FACP discussing the SUPRAME trial comparing IMA203 (engineered TCR-T cell therapy) vs investigators choice in previously treated advanced #cutaneousmelanoma Abstract number | TPS2673 meetings.asco.org/abstracts-pres… #SkinCancer #SKcsm

Available in #CancerScope! A 7-year study in The Lancet Oncology shows nivolumab + ipilimumab helps people w/ melanoma brain metastases live longer 🧠 CANCER Section Editor Jason Luke, MD, FACP explains why this combination is now the go-to treatment acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… OncoAlert

For the immunologists still on X science.org/doi/10.1126/sc…